Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders

Diagnostic and Statistical Manual of Mental Disorders

American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369 · see citing works

Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor

Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633 · see citing works

Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish

Gaoni, Y., & Mechoulam, R. (1964) · Journal of the American Chemical Society · doi:10.1021/ja01062a046 · Cited by 2,407 · see citing works

Psychological autopsy studies of suicide: a systematic review.

CAVANAGH, J. T. O., CARSON, A. J., SHARPE, M., & LAWRIE, S. M. (2003) · Psychological Medicine · doi:10.1017/s0033291702006943 · Cited by 2,207 · see citing works

The diverse CB 1 and CB 2 receptor pharmacology of three plant cannabinoids: Δ 9 ‐tetrahydrocannabinol, cannabidiol and Δ 9 ‐tetrahydrocannabivarin

Pertwee, R. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707442 · Cited by 1,953 · see citing works

Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation

Willner, P. (1997) · Psychopharmacology · doi:10.1007/s002130050456 · Cited by 1,832 · see citing works

Endocannabinoid-Mediated Control of Synaptic Transmission

Kano, M., Ohno‐Shosaku, T., Hashimotodani, Y., Uchigashima, M., & Watanabe, M. (2009) · Physiological Reviews · doi:10.1152/physrev.00019.2008 · Cited by 1,529 · see citing works

Schizophrenia as a Disorder of Neurodevelopment

Lewis, D. A., & Levitt, P. (2002) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.25.112701.142754 · Cited by 1,163 · see citing works

Chronic mild stress-induced anhedonia: A realistic animal model of depression

Willner, P., Muscat, R., & Papp, M. (1992) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(05)80194-0 · Cited by 1,160 · see citing works

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia

Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059 · see citing works

Cannabidiol is a negative allosteric modulator of the cannabinoid CB ₁ receptor

Laprairie, R. B., Bagher, A. M., Kelly, M. E. M., & Denovan‐Wright, E. M. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13250 · Cited by 1,039 · see citing works

Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome

Devinsky, O., Patel, A. D., Cross, J. H., Villanueva, V., Wirrell, E. C., Privitera, M., Greenwood, S. M., Roberts, C., Checketts, D., VanLandingham, K. E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714631 · Cited by 1,015 · see citing works

Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.

Devinsky, O., Cilio, M. R., Cross, H., Fernandez‐Ruiz, J., French, J., Hill, C., Katz, R., Di Marzo, V., Jutras‐Aswad, D., Notcutt, W. G., et al. (2014) · Epilepsia · doi:10.1111/epi.12631 · Cited by 1,000 · see citing works

Psychiatric diagnoses in 3275 suicides: a meta-analysis

Arsenault-Lapierre, G., Kim, C., & Turecki, G. (2004) · BMC Psychiatry · doi:10.1186/1471-244x-4-37 · Cited by 985 · see citing works

Effects of cannabinoids and cannabinoid‐enriched <i>Cannabis</i> extracts on TRP channels and endocannabinoid metabolic enzymes

De Petrocellis, L., Ligresti, A., Moriello, A. S., Allarà, M., Bisogno, T., Petrosino, S., Stott, C. G., & Di Marzo, V. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01166.x · Cited by 946 · see citing works

The GABAergic deficit hypothesis of major depressive disorder

Luscher, B., Shen, Q., & Sahir, N. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.120 · Cited by 934 · see citing works

Excess early mortality in schizophrenia.

Laursen, T. M., Nordentoft, M., & Mortensen, P. B. (2014) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032813-153657 · Cited by 913 · see citing works

Agonistic properties of cannabidiol at 5-HT1a receptors

Russo, E. B., Burnett, A., Hall, B., & Parker, K. K. (2005) · Neurochemical Research · doi:10.1007/s11064-005-6978-1 · Cited by 878 · see citing works

Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb

Izzo, A. A., Borrelli, F., Capasso, R., Marzo, V. D., & Mechoulam, R. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.07.006 · Cited by 851 · see citing works

Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial

Daly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., Lane, R., Lim, P., Duca, A. R., Hough, D., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1189 · Cited by 795 · see citing works

Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients

Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., de Oliveira, D. C. G., De Martinis, B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.6 · Cited by 771 · see citing works

Animal models of schizophrenia

Jones, C., Watson, D., & Fone, K. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01386.x · Cited by 771 · see citing works

Cannabidiol displays unexpectedly high potency as an antagonist of CB 1 and CB 2 receptor agonists in vitro

Thomas, A., Baillie, G. L., Phillips, A. M., Razdan, R. K., Ross, R. A., & Pertwee, R. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707133 · Cited by 763 · see citing works

Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial

Daly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3739 · Cited by 718 · see citing works

Cannabidiol as a Potential Treatment for Anxiety Disorders

Blessing, E., Steenkamp, M. M., Manzanares, J., & Marmar, C. R. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0387-1 · Cited by 717 · see citing works

Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology

Bhattacharyya, S., Morrison, P. D., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., Winton-Brown, T., Nosarti, C., O' Carroll, C. M., Seal, M., Allen, P., et al. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.184 · Cited by 680 · see citing works

Cannabidiol: State of the art and new challenges for therapeutic applications

Pisanti, S., Malfitano, A. M., Ciaglia, E., Lamberti, A., Ranieri, R., Cuomo, G., Abate, M., Faggiana, G., Proto, M., Fiore, D., et al. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.041 · Cited by 625 · see citing works

Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial

McGuire, P., Robson, P., Cubala, W. J., Vasile, D., Morrison, P. D., Barron, R., Taylor, A., & Wright, S. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17030325 · Cited by 617 · see citing works

Action of cannabidiol on the anxiety and other effects produced by ?9-THC in normal subjects

Zuardi, A. W., Shirakawa, I., Finkelfarb, E., & Karniol, I. G. (1982) · Psychopharmacology · doi:10.1007/bf00432554 · Cited by 608 · see citing works

Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)

Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz039 · Cited by 606 · see citing works

Molecular Targets of Cannabidiol in Neurological Disorders

Bih, C. I., Chen, T., Nunn, A. V. W., Bazelot, M., Dallas, M. L., & Whalley, B. J. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0377-3 · Cited by 582 · see citing works

Cannabidiol (CBD) and its analogs: a review of their effects on inflammation.

Burstein, S. (2015) · Bioorganic &amp; Medicinal Chemistry · doi:10.1016/j.bmc.2015.01.059 · Cited by 573 · see citing works

Antitumor Activity of Plant Cannabinoids with Emphasis on the Effect of Cannabidiol on Human Breast Carcinoma

Ligresti, A., Moriello, A. S., Starowicz, K., Matias, I., Pisanti, S., PETROCELLIS, L. D., Laezza, C., Portella, G., Bifulco, M., & Marzo, V. D. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.105247 · Cited by 569 · see citing works

A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans

Millar, S., Stone, N. L., Yates, A. S., & O’Sullivan, S. E. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01365 · Cited by 567 · see citing works

Safety and side effects of cannabidiol, a Cannabis sativa constituent

Machado Bergamaschi, M., Helena Costa Queiroz, R., Waldo Zuardi, A., & Alexandre S. Crippa, J. (2011) · Current Drug Safety · doi:10.2174/157488611798280924 · Cited by 558 · see citing works

Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: A preliminary report

Crippa, J. A. S., Derenusson, G. N., Ferrari, T. B., Wichert-Ana, L., Duran, F. L., Martin-Santos, R., Simões, M. V., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., et al. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110379283 · Cited by 535 · see citing works

Are cannabidiol and Δ9‐tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review

McPartland, J. M., Duncan, M., Marzo, V. D., & Pertwee, R. G. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12944 · Cited by 526 · see citing works

Generalized Anxiety Disorder

Stein, M. B., & Sareen, J. (2015) · New England Journal of Medicine · doi:10.1056/nejmcp1502514 · Cited by 523 · see citing works

Cannabidiol—recent advances

Mechoulam, R., Peters, M., Murillo‐Rodriguez, E., & Hanuš, L. O. (2007) · Chemistry &amp; Biodiversity · doi:10.1002/cbdv.200790147 · Cited by 515 · see citing works

Hashish—I

Mechoulam, R., & Shvo, Y. (1963) · Tetrahedron · doi:10.1016/0040-4020(63)85022-x · Cited by 486 · see citing works

Distinct Effects of Δ9-Tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing

Fusar-Poli, P., Crippa, J. A., Bhattacharyya, S., Borgwardt, S. J., Allen, P., Martin-Santos, R., Seal, M., Surguladze, S. A., O’Carrol, C., Atakan, Z., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2008.519 · Cited by 465 · see citing works

Cannabidiol in Anxiety and Sleep: A Large Case Series

Shannon, S. M., Lewis, N., Lee, H. J., & Hughes, S. (2019) · The Permanente Journal · doi:10.7812/tpp/18-041 · Cited by 433 · see citing works

Nabiximols for Opioid-Treated Cancer Patients With Poorly-Controlled Chronic Pain: A Randomized, Placebo-Controlled, Graded-Dose Trial

Portenoy, R. K., Ganae-Motan, E. D., Allende, S., Yanagihara, R., Shaiova, L., Weinstein, S., McQuade, R., Wright, S., & Fallon, M. T. (2012) · The Journal of Pain · doi:10.1016/j.jpain.2012.01.003 · Cited by 420 · see citing works

Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug

Zuardi, A. W., Crippa, J. A. S., Hallak, J. E. C., Moreira, F. A., & Guimarães, F. S. (2006) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2006000400001 · Cited by 402 · see citing works

Cannabidiol and Other Cannabinoids Reduce Microglial Activation In Vitro and In Vivo: Relevance to Alzheimer’s Disease

Martín-Moreno, A. M., Reigada, D., Ramírez, B. G., Mechoulam, R., Innamorato, N. G., Cuadrado, A., & CEBALLOS, M. L. D. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.071290 · Cited by 402 · see citing works

Cortical GABAergic Dysfunction in Stress and Depression: New Insights for Therapeutic Interventions

Fogaça, M. V., & Duman, R. S. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00087 · Cited by 396 · see citing works

Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia

Corfas, G., Roy, K., & Buxbaum, J. D. (2004) · Nature Neuroscience · doi:10.1038/nn1258 · Cited by 388 · see citing works

Antianxiety effect of cannabidiol in the elevated plus-maze

Guimarães, F. S., Chiaretti, T. M., Graeff, F. G., & Zuardi, A. W. (1990) · Psychopharmacology · doi:10.1007/bf02244012 · Cited by 379 · see citing works

Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors

Kathmann, M., Flau, K., Redmer, A., Tränkle, C., & Schlicker, E. (2006) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-006-0033-x · Cited by 379 · see citing works

Antidepressant‐like effects of cannabidiol in mice: possible involvement of 5‐HT_1Areceptors

Zanelati, T., Biojone, C., Moreira, F., Guimarães, F., & Joca, S. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00521.x · Cited by 366 · see citing works

Effects of ipsapirone and cannabidiol on human experimental anxiety

Zuardi, A. W., Cosme, R. A., Graeff, F. G., & Guimarães, F. S. (1993) · Journal of Psychopharmacology · doi:10.1177/026988119300700112 · Cited by 364 · see citing works

Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats

Campos, A. C., & Guimarães, F. S. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1168-x · Cited by 364 · see citing works

Cannabidiol for the treatment of psychosis in Parkinson's disease

Zuardi, A., Crippa, J., Hallak, J., Pinto, J., Chagas, M., Rodrigues, G., Dursun, S., & Tumas, V. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108096519 · Cited by 355 · see citing works

Symptoms, signs, and diagnosis of schizophrenia

Andreasen, N. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91325-4 · Cited by 344 · see citing works

Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial

Hurd, Y. L., Spriggs, S. A., Alishayev, J., Winkel, G. H., Gurgov, K., Kudrich, C., Oprescu, A. M., & Salsitz, E. A. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.18101191 · Cited by 344 · see citing works

Plant-Derived Cannabinoids Modulate the Activity of Transient Receptor Potential Channels of Ankyrin Type-1 and Melastatin Type-8

PETROCELLIS, L. D., Vellani, V., Moriello, A. S., Marini, P., Magherini, P. C., Orlando, P., & Marzo, V. D. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.134809 · Cited by 337 · see citing works

The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo

Whyte, L. S., Ryberg, E., Sims, N. A., Ridge, S. A., Mackie, K., Greasley, P. J., Ross, R. A., & Rogers, M. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902743106 · Cited by 331 · see citing works

Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes

Jiang, R., Yamaori, S., Takeda, S., Yamamoto, I., & Watanabe, K. (2011) · Life Sciences · doi:10.1016/j.lfs.2011.05.018 · Cited by 322 · see citing works

The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system

Campos, A. C., Ortega, Z., Palazuelos, J., Fogaça, M. V., Aguiar, D. C., Díaz-Alonso, J., Ortega-Gutiérrez, S., Vázquez-Villa, H., Moreira, F. A., Guzmán, M., et al. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001502 · Cited by 313 · see citing works

Pharmacological characterization of cannabinoids in the elevated plus maze.

Onaivi, E. S., Green, M. R., & Martin, B. R. (1990) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)13195-9 · Cited by 312 · see citing works

DSM-5 Criteria and Depression Severity: Implications for Clinical Practice

Tolentino, J. C., & Schmidt, S. L. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00450 · Cited by 311 · see citing works

Effects of cannabidiol (CBD) on regional cerebral blood flow

Crippa, J. A. D. S., Zuardi, A. W., Garrido, G. E. J., Wichert-Ana, L., Guarnieri, R., Ferrari, L., Azevedo-Marques, P. M., Hallak, J. E. C., McGuire, P. K., & Busatto, G. F. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300340 · Cited by 307 · see citing works

Cannabidiol interferes with the effects of Δ9-tetrahydrocannabinol in man

Karniol, I. G., Shirakawa, I., Kasinski, N., Pfeferman, A., & Carlini, E. A. (1974) · European Journal of Pharmacology · doi:10.1016/0014-2999(74)90129-0 · Cited by 303 · see citing works

Human Metabolites of Cannabidiol: A Review on Their Formation, Biological Activity, and Relevance in Therapy

Ujváry, I., & Hanuš, L. (2016) · Cannabis and Cannabinoid Research · doi:10.1089/can.2015.0012 · Cited by 302 · see citing works

Structure of Cannabidiol, a Product Isolated from the Marihuana Extract of Minnesota Wild Hemp. I

ADAMS, R. L. P., Hunt, M., & Clark, J. H. (1940) · Journal of the American Chemical Society · doi:10.1021/ja01858a058 · Cited by 302 · see citing works

Acute Effects of a Single, Oral dose of d9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) Administration in Healthy Volunteers

Martín‐Santos, R., Crippa, J. A. S., Batalla, A., Bhattacharyya, S., Atakan, Z., Borgwardt, S., Allen, P., Seal, M. L., Langohr, K., Farré, M., et al. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802884780 · Cited by 298 · see citing works

Depression and anxiety

Tiller, J. (2012) · Medical Journal of Australia · doi:10.5694/mja12.10628 · Cited by 291 · see citing works

A Cross-Sectional Study of Cannabidiol Users

Corroon, J., & Phillips, J. A. (2018) · Cannabis and Cannabinoid Research · doi:10.1089/can.2018.0006 · Cited by 290 · see citing works

A systematic review of comparative efficacy of treatments and controls for depression

Khan, A., Faucett, J., Lichtenberg, P., Kirsch, I., & Brown, W. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041778 · Cited by 288 · see citing works

Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors

Linge, R., Jiménez-Sánchez, L., Campa, L., Pilar-Cuéllar, F., Vidal, R., Pazos, Á., Adell, A., & Díaz, Á. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.12.017 · Cited by 285 · see citing works

5‐HT_1Areceptors are involved in the cannabidiol‐induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats

Resstel, L. B. M., Tavares, R. F., Lisboa, S. F. S., Joca, S. R. L., Corrêa, F. M. A., & Guimarães, F. S. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00046.x · Cited by 283 · see citing works

Pharmacokinetics and Metabolism of the Plant Cannabinoids, Δ 9-Tetrahydrocannibinol, Cannabidiol and Cannabinol

Huestis, M. A. (2005) · Handbook of experimental pharmacology · doi:10.1007/3-540-26573-2_23 · Cited by 278 · see citing works

Neuroprotective and Blood-Retinal Barrier-Preserving Effects of Cannabidiol in Experimental Diabetes

El‐Remessy, A. B., Al‐Shabrawey, M., Khalifa, Y. M., Tsai, N., Caldwell, R. B., & Liou, G. I. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.050500 · Cited by 275 · see citing works

Antidepressant-like effect of Δ9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L.

El‐Alfy, A. T., Ivey, K., Robinson, K., Ahmed, S. A., Radwan, M. M., Slade, D., Khan, I. A., ElSohly, M. A., & Ross, S. A. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.03.004 · Cited by 271 · see citing works

Endocannabinoid signalling in the blood of patients with schizophrenia.

Marchi, N. D., PETROCELLIS, L. D., Orlando, P., Daniele, F., Fezza, F., & Marzo, V. D. (2003) · Lipids in Health and Disease · doi:10.1186/1476-511x-2-5 · Cited by 266 · see citing works

Nabiximols as an Agonist Replacement Therapy During Cannabis Withdrawal: A Randomized Clinical Trial

Allsop, D. J., Copeland, J., Lintzeris, N., Dunlop, A. J., Montebello, M., Sadler, C., Rivas, G. R., Holland, R. M., Muhleisen, P., Norberg, M. M., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.3947 · Cited by 266 · see citing works

Facilitation of contextual fear memory extinction and anti-anxiogenic effects of AM404 and cannabidiol in conditioned rats

de Bitencourt, R. M., Pamplona, F. A., & Takahashi, R. N. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.07.001 · Cited by 264 · see citing works

Antipsychotic effect of cannabidiol.

Zuardi, A. W., Morais, S. L., Guimarães, F. S., & Mechoulam, R. (1995) · PubMed · Cited by 264 · see citing works

A systematic review of the antipsychotic properties of cannabidiol in humans

Iseger, T. A., & Bossong, M. G. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.01.033 · Cited by 261 · see citing works

Cannabidiol, a non‐psychotropic component of cannabis, attenuates vomiting and nausea‐like behaviour via indirect agonism of 5‐HT_1A somatodendritic autoreceptors in the dorsal raphe nucleus

Rock, E., Bolognini, D., Limebeer, C., Cascio, M., Anavi‐Goffer, S., Fletcher, P., Mechoulam, R., Pertwee, R., & Parker, L. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01621.x · Cited by 255 · see citing works

Modulation of Mediotemporal and Ventrostriatal Function in Humans by Δ9-Tetrahydrocannabinol

Bhattacharyya, S., Fusar‐Poli, P., Borgwardt, S., Martín‐Santos, R., Nosarti, C., O’Carroll, C., Allen, P., Seal, M. L., Fletcher, P. C., Crippa, J. A. S., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.17 · Cited by 246 · see citing works

Suicide Risk in Bipolar Disorder: A Brief Review

Dome, P., Rihmer, Z., & Gonda, X. (2019) · Medicina · doi:10.3390/medicina55080403 · Cited by 246 · see citing works

The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABA A receptors

Bakas, T., van Nieuwenhuijzen, P. S., Devenish, S. O., McGregor, I. S., Arnold, J. C., & Chebib, M. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.02.022 · Cited by 246 · see citing works

The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial

Boggs, D. L., Surti, T. S., Gupta, A., Gupta, S., Niciu, M. J., Pittman, B. P., Martin, A. M. S., Thurnauer, H., Davies, A., D’Souza, D. C., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4885-9 · Cited by 243 · see citing works

Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol

Boggs, D. L., Nguyen, J. D., Morgenson, D., Taffe, M. A., & Ranganathan, M. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.209 · Cited by 236 · see citing works

Cannabidiol: A Promising Drug for Neurodegenerative Disorders?

Iuvone, T., Esposito, G., Filippis, D. D., Scuderi, C., & Steardo, L. (2009) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00065.x · Cited by 215 · see citing works

Cannabinoid- and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses

Sylantyev, S., Jensen, T. P., Ross, R. A., & Rusakov, D. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1211204110 · Cited by 213 · see citing works

The anxiolytic effects of cannabidiol in chronically stressed mice are mediated by the endocannabinoid system: Role of neurogenesis and dendritic remodeling

Fogaça, M. V., Campos, A. C., Coelho, L. D., Duman, R. S., & Guimarães, F. S. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.03.001 · Cited by 208 · see citing works

Cannabinoid receptor CB1 mediates baseline and activity-induced survival of new neurons in adult hippocampal neurogenesis

Wolf, S. A., Bick-Sander, A., Fabel, K., Leal-Galicia, P., Tauber, S., Ramirez-Rodriguez, G., Müller, A., Melnik, A., Waltinger, T. P., Ullrich, O., et al. (2010) · Cell Communication and Signaling · doi:10.1186/1478-811x-8-12 · Cited by 208 · see citing works

Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test

Moreira, F. A., Aguiar, D. C., & Guimarães, F. S. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.06.004 · Cited by 207 · see citing works

A behavioural comparison of acute and chronic Δ9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice

Long, L. E., Chesworth, R., Huang, X., McGregor, I. S., Arnold, J. C., & Karl, T. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990605 · Cited by 206 · see citing works

Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice

Moreira, F. A., & Guimarães, F. S. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.02.040 · Cited by 206 · see citing works

Cannabidiol Induces Rapid and Sustained Antidepressant-Like Effects Through Increased BDNF Signaling and Synaptogenesis in the Prefrontal Cortex

Sales, A. J., Fogaça, M. V., Sartim, A. G., Pereira, V. S., Wegener, G., Guimarães, F. S., & Joca, S. R. L. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1143-4 · Cited by 198 · see citing works

Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study

Kahn, R. S., Rossum, I. W.-V., Leucht, S., McGuire, P. K., Lewis, S. W., Leboyer, M., Arango, C., Dazzan, P., Drake, R., Heres, S., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30252-9 · Cited by 194 · see citing works

Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis‐like disease in C57BL/6 mice

Kozela, E., Lev, N., Kaushansky, N., Eilam, R., Rimmerman, N., Levy, R., Ben‐Nun, A., Juknat, A., & Vogel, Z. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01379.x · Cited by 193 · see citing works

Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer

Aviello, G., Romano, B., Borrelli, F., Capasso, R., Gallo, L., Piscitelli, F., Marzo, V. D., & Izzo, A. A. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0856-x · Cited by 191 · see citing works

Effects of cannabidiol in animal models predictive of antipsychotic activity

Zuardi, A. W., Antunes Rodrigues, J., & Cunha, J. M. (1991) · Psychopharmacology · doi:10.1007/bf02244189 · Cited by 191 · see citing works

GABAergic Mechanisms in Schizophrenia: Linking Postmortem and In Vivo Studies

de Jonge, J. C., Vinkers, C. H., Pol, H. E. H., & Marsman, A. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00118 · Cited by 185 · see citing works

Glutamate dysregulation and glutamatergic therapeutics for PTSD: Evidence from human studies

Averill, L. A., Purohit, P., Averill, C. L., Boesl, M. A., Krystal, J. H., & Abdallah, C. G. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.11.064 · Cited by 184 · see citing works

Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: A randomised, double-blind, placebo-controlled study in cannabis users

Hindocha, C., Freeman, T. P., Schäfer, G., Gardener, C., Das, R., Morgan, C. J. A., & Curran, H. V. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.11.014 · Cited by 183 · see citing works

Effects of cannabidiol and diazepam on behavioral and cardiovascular responses induced by contextual conditioned fear in rats

Resstel, L. B. M., Joca, S. R. L., Moreira, F. A., Corrêa, F. M. A., & Guimarães, F. S. (2006) · Behavioural Brain Research · doi:10.1016/j.bbr.2006.05.016 · Cited by 182 · see citing works

Complex pharmacology of natural cannabivoids: Evidence for partial agonist activity of Δ9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors

Petitet, F., Jeantaud, B., Reibaud, M., Impérato, A., & Dubroeucq, M. C. (1998) · Life Sciences · doi:10.1016/s0024-3205(98)00238-0 · Cited by 180 · see citing works

Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose

Seeman, P. M. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.195 · Cited by 177 · see citing works

Cannabidiol Reverses MK-801-Induced Disruption of Prepulse Inhibition in Mice

Long, L. E., Malone, D. T., & TAYLOR, D. A. H. B. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300838 · Cited by 173 · see citing works

Effect of low doses of ?9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats

Parker, L. A., Burton, P., Sorge, R. E., Yakiwchuk, C., & Mechoulam, R. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1825-7 · Cited by 171 · see citing works

The Heterogeneity of Mental Health Assessment

Newson, J. J., Hunter, D., & Thiagarajan, T. C. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00076 · Cited by 166 · see citing works

Modulation of effective connectivity during emotional processing by Δ9-tetrahydrocannabinol and cannabidiol

Fusar-Poli, P., Allen, P., Bhattacharyya, S., Crippa, J. A., Mechelli, A., Borgwardt, S., Martin-Santos, R., Seal, M. L., O'Carrol, C., Atakan, Z., et al. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990617 · Cited by 163 · see citing works

Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series

Elms, L., Shannon, S. M., Hughes, S., & Lewis, N. (2018) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2018.0437 · Cited by 156 · see citing works

Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder

Pretzsch, C. M., Freyberg, J., Voinescu, B., Lythgoe, D. J., Horder, J., Méndez, M. A., Wichers, R., Ajram, L. A., Ivin, G., Heasman, M., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0333-8 · Cited by 156 · see citing works

On disruption of fear memory by reconsolidation blockade: evidence from cannabidiol treatment

Stern, C. A. J., Gazarini, L., Takahashi, R. N., Guimarães, F. S., & Bertoglio, L. J. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.63 · Cited by 156 · see citing works

Antidepressant-like effect of cannabidiol injection into the ventral medial prefrontal cortex-Possible involvement of 5-HT1A and CB1 receptors

Sartim, A. G., Guimarães, F. S., & Joca, S. R. L. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.01.033 · Cited by 156 · see citing works

Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis sativa

Schier, A. R. D. M., Ribeiro, N. D. C. R., Coutinho, D. C. O., Machado, S. E. D. C., Arias-Carrión, Ó., Crippa, J. A. S., Zuardi, A. W., Nardi, A. E., & Silva, A. R. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666140612114838 · Cited by 154 · see citing works

Effects of intra-prelimbic prefrontal cortex injection of cannabidiol on anxiety-like behavior: involvement of 5HT1A receptors and previous stressful experience

Fogaça, M. V., Reis, F. M. C. V., Campos, A. C., & Guimarães, F. S. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.10.012 · Cited by 153 · see citing works

Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis

Bhattacharyya, S., Wilson, R. P., Appiah‐Kusi, E., O’Neill, A., Brammer, M. J., Pérez, J., Murray, R. M., Allen, P., Bossong, M. G., & McGuire, P. K. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.2309 · Cited by 151 · see citing works

Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol

Gomes, F. V., Llorente, R., Del Bel, E. A., Viveros, M.-P., López-Gallardo, M., & Guimarães, F. S. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.01.015 · Cited by 147 · see citing works

Glutamatergic Dysfunction and Glutamatergic Compounds for Major Psychiatric Disorders: Evidence From Clinical Neuroimaging Studies

Li, C.-T., Yang, K.-C., & Lin, W.-C. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00767 · Cited by 147 · see citing works

Modulation of auditory and visual processing by delta-9-tetrahydrocannabinol and cannabidiol: an FMRI study

Winton-Brown, T. T., Allen, P., Bhattacharrya, S., Borgwardt, S. J., Fusar-Poli, P., Crippa, J. A., Seal, M. L., Martin-Santos, R., Ffytche, D., Zuardi, A. W., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.17 · Cited by 146 · see citing works

Involvement of the prelimbic prefrontal cortex on cannabidiol-induced attenuation of contextual conditioned fear in rats

Lemos, J. I., Resstel, L. B., & Guimarães, F. S. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.09.045 · Cited by 146 · see citing works

Improved Social Interaction, Recognition and Working Memory with Cannabidiol Treatment in a Prenatal Infection (poly I:C) Rat Model

Osborne, A. L., Solowij, N., Babic, I., Huang, X., & Weston–Green, K. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.40 · Cited by 141 · see citing works

Cannabidiol inhibitory effect on marble-burying behaviour: involvement of CB1 receptors

Casarotto, P. C., Gomes, F. V., Resstel, L. B. M., & Guimarães, F. S. (2010) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32833b33c5 · Cited by 141 · see citing works

Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5HT1A receptors

Campos, A. C., Ferreira, F. R., & Guimarães, F. S. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.08.012 · Cited by 139 · see citing works

Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings

Elsaid, S., Kloiber, S. M., & Foll, B. L. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.06.005 · Cited by 136 · see citing works

Influence of single and repeated cannabidiol administration on emotional behavior and markers of cell proliferation and neurogenesis in non-stressed mice

Schiavon, A. P., Bonato, J. M., Milani, H., Guimarães, F. S., & Weffort de Oliveira, R. M. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.06.017 · Cited by 135 · see citing works

Endocannabinoid System Components as Potential Biomarkers in Psychiatry

Navarrete, F., García‐Gutiérrez, M. S., Barba, R. J., Rubio, G., Gasparyan, A., Austrich-Olivares, A., & Manzanares, J. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00315 · Cited by 134 · see citing works

Cannabidiol Counteracts Amphetamine-Induced Neuronal and Behavioral Sensitization of the Mesolimbic Dopamine Pathway through a Novel mTOR/p70S6 Kinase Signaling Pathway

Renard, J., Loureiro, M., Rosen, L. G., Zunder, J. S., Oliveira, C. D., Schmid, S., Rushlow, W. J., & Laviolette, S. R. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.3387-15.2016 · Cited by 131 · see citing works

Therapeutic Effects of Prolonged Cannabidiol Treatment on Psychological Symptoms and Cognitive Function in Regular Cannabis Users: A Pragmatic Open-Label Clinical Trial

Solowij, N., Broyd, S. J., Beale, C., Prick, J.-A., Greenwood, L., van Hell, H., Suo, C., Galettis, P., Pai, N. B., Fu, S., et al. (2018) · Cannabis and Cannabinoid Research · doi:10.1089/can.2017.0043 · Cited by 130 · see citing works

Effects of cannabinoids on catecholamine uptake and release in hypothalamic and striatal synaptosomes.

Poddar, M. K., & Dewey, W. L. (1980) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)32131-2 · Cited by 126 · see citing works

Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD)

Hallak, J. E. C., Machado‐de‐Sousa, J. P., Crippa, J. A. S., Sanches, R. F., Trzesniak, C. M. F., Chaves, C., Bernardo, S. A., Regalo, S. C. H., & Zuardi, A. W. (2010) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462010000100011 · Cited by 125 · see citing works

Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Δ9-tetrahydrocannabinol

Vann, R. E., Gamage, T. F., Warner, J. A., Marshall, E. M., Taylor, N. L., Martin, B. R., & Wiley, J. L. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2007.11.017 · Cited by 122 · see citing works

Depression subtyping based on evolutionary psychiatry: Proximate mechanisms and ultimate functions

Rantala, M. J., Luoto, S., Krams, I. A., & Karlsson, H. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2017.10.012 · Cited by 121 · see citing works

Antidepressant-like effect induced by Cannabidiol is dependent on brain serotonin levels

Sales, A. J., Crestani, C. C., Guimarães, F. S., & Joca, S. R. L. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.06.002 · Cited by 118 · see citing works

Intra-dorsal periaqueductal gray administration of cannabidiol blocks panic-like response by activating 5-HT1A receptors

Soares, V. D. P., Campos, A. C., Bortoli, V. C. D., Zangrossi, H., Guimarães, F. S., & Zuardi, A. W. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.05.004 · Cited by 112 · see citing works

Antidepressants plus benzodiazepines for adults with major depression

Ogawa, Y., Takeshima, N., Hayasaka, Y., Tajika, A., Watanabe, N., Streiner, D. L., & Furukawa, T. A. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001026.pub2 · Cited by 110 · see citing works

Prohedonic effect of cannabidiol in a rat model of depression

Shoval, G., Shbiro, L., Hershkovitz, L., Hazut, N., Zalsman, G., Mechoulam, R., & Weller, A. (2016) · Neuropsychobiology · doi:10.1159/000443890 · Cited by 110 · see citing works

Modulation of rat brain opioid receptors by cannabinoids.

VAYSSE, P. J. ‐., Gardner, E. L., & Zukin, R. S. (1987) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-5347(25)00276-9 · Cited by 102 · see citing works

Distinct Neurobehavioural Effects of Cannabidiol in Transmembrane Domain Neuregulin 1 Mutant Mice

Long, L. E., Chesworth, R., Huang, X., Wong, A., Spiro, A. S., McGregor, I. S., Arnold, J. C., & Karl, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034129 · Cited by 102 · see citing works

Cannabidiol for the treatment of <i>cannabis</i> withdrawal syndrome: a case report: CBD and cannabis withdrawal

Crippa, J. A. S., Hallak, J. E. C., Machado-de-Sousa, J. P., Queiroz, R. H. C., Bergamaschi, M., Chagas, M. H. N., & Zuardi, A. W. (2013) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12018 · Cited by 101 · see citing works

Pharmacokinetics of oral and intravenous cannabidiol and its antidepressant-like effects in chronic mild stress mouse model

Xu, C., Chang, T., Du, Y., Yu, C., Tan, X. L., & Li, X. (2019) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2019.103202 · Cited by 99 · see citing works

Effects of Chronic Cannabidiol Treatment in the Rat Chronic Unpredictable Mild Stress Model of Depression

Gáll, Z., Farkas, S., Albert, Á., Ferencz, E., Vancea, S., Urkon, M., & Kolcsár, M. (2020) · Biomolecules · doi:10.3390/biom10050801 · Cited by 99 · see citing works

Cannabinoids inhibit the synaptic uptake of adenosine and dopamine in the rat and mouse striatum

Pandolfo, P., Silveirinha, V., dos Santos‐Rodrigues, A., Venance, L., Ledent, C. A., Takahashi, R. N., Cunha, R. A., & Köfalvi, A. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.01.013 · Cited by 96 · see citing works

Cannabidiol disrupts the consolidation of specific and generalized fear memories via dorsal hippocampus CB1 and CB2 receptors

Stern, C. A. J., da Silva, T. R., Raymundi, A. M., de Souza, C. P., Sato, V., Kato, L., Guimarães, F. S., Andreatini, R., Takahashi, R. N., & Bertoglio, L. J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.07.024 · Cited by 96 · see citing works

Anxiogenic-like effects of chronic cannabidiol administration in rats

ElBatsh, M. M., Assareh, N., Marsden, C. A., & Kendall, D. A. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2566-z · Cited by 93 · see citing works

Peripheral Endocannabinoid System Dysregulation in First-Episode Psychosis

(CIBERSAM), F. T. F.-P. S. D. I. B. E. R. D. S. M., Bioque, M., García‐Bueno, B., MacDowell, K. S., Meseguer, A., Sáiz, P. A., Parellada, M., González-Pinto, A. M., Rodríguez–Jiménez, R., Lobo, A., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.165 · Cited by 92 · see citing works

Cannabidiol exhibits anxiolytic but not antipsychotic property evaluated in the social interaction test

de Almeida, V., Levin, R. R., Peres, F. F., Niigaki, S. T., Calzavara, M. B., Zuardi, A. W., Hallak, J. E. C., Crippa, J. A. S., & Abílio, V. C. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.10.024 · Cited by 90 · see citing works

Cannabidiol does not display drug abuse potential in mice behavior

Viudez‐Martínez, A., García‐Gutiérrez, M. S., Medrano-Relinque, J., Navarrón, C. M., Navarrete, F., & Manzanares, J. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0032-8 · Cited by 90 · see citing works

Effect of cannabidiol in a MK-801-rodent model of aspects of Schizophrenia

Gururajan, A., TAYLOR, D. A. H. B., & Malone, D. T. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.03.053 · Cited by 89 · see citing works

Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia

Štark, T., Kučerová, J., Iannotti, F. A., D’Addario, C., Marco, R. D., Pekařík, V., Dražanová, E., Piscitelli, F., Bari, M., Babinská, Z., et al. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.11.035 · Cited by 89 · see citing works

Cannabidiol attenuates sensorimotor gating disruption and molecular changes induced by chronic antagonism of NMDA receptors in mice

Gomes, F. V., Issy, A. C., Ferreira, F. R., Viveros, M.-P., Del Bel, E. A., & Guimarães, F. S. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu041 · Cited by 89 · see citing works

Infusion of cannabidiol into infralimbic cortex facilitates fear extinction via CB1 receptors

Monte, F. H. D., de Souza, R. R., de Bitencourt, R. M., Kroon, J. A. V., & Takahashi, R. N. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.04.045 · Cited by 88 · see citing works

Cannabidiol attenuates behavioral changes in a rodent model of schizophrenia through 5-HT1A, but not CB1 and CB2 receptors

da Silva, N. R., Gomes, F. V., Sonego, A. B., da Silva, N. R., & Guimarães, F. S. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104749 · Cited by 88 · see citing works

Acute Cannabinoids Produce Robust Anxiety-Like and Locomotor Effects in Mice, but Long-Term Consequences Are Age- and Sex-Dependent

Kasten, C. R., Zhang, Y., & Boehm, S. L. (2019) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2019.00032 · Cited by 86 · see citing works

Administration of cannabidiol and imipramine induces antidepressant-like effects in the forced swimming test and increases brain-derived neurotrophic factor levels in the rat amygdala

Réus, G. Z., Stringari, R. B., Ribeiro, K. F., Luft, T., Abelaira, H. M., Fries, G. R., Aguiar, B. W., Kapczinski, F., Hallak, J. E., Zuardi, A. W., et al. (2011) · Acta Neuropsychiatrica · doi:10.1111/j.1601-5215.2011.00579.x · Cited by 86 · see citing works

Improving Current Treatments for Schizophrenia

Marić, N. P., Jovicic, M. J., Mihaljevic, M. M., & Miljević, Č. (2016) · Drug Development Research · doi:10.1002/ddr.21337 · Cited by 85 · see citing works

Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation?

Zlebnik, N. E., & Cheer, J. F. (2016) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-070815-014038 · Cited by 79 · see citing works

Cannabidiol and clozapine reverse MK-801-induced deficits in social interaction and hyperactivity in Sprague–Dawley rats

Gururajan, A., TAYLOR, D. A. H. B., & Malone, D. T. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112441865 · Cited by 77 · see citing works

The Utility of Cannabidiol in the Treatment of Refractory Epilepsy

Reddy, D. S. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.441 · Cited by 77 · see citing works

Delta-9-Tetrahydrocannabinol/Cannabidiol (Sativex®): A Review of Its Use in Patients with Moderate to Severe Spasticity Due to Multiple Sclerosis

Syed, Y. Y., McKeage, K., & Scott, L. J. (2014) · Drugs · doi:10.1007/s40265-014-0197-5 · Cited by 76 · see citing works

Prolonged Cannabidiol Treatment Effects on Hippocampal Subfield Volumes in Current Cannabis Users

Beale, C., Broyd, S. J., Chye, Y., Suo, C., Schira, M. M., Galettis, P., Martin, J. H., Yücel, M., & Solowij, N. (2018) · Cannabis and Cannabinoid Research · doi:10.1089/can.2017.0047 · Cited by 76 · see citing works

Effects of cannabidiol in males and females in two different rat models of depression

Shbiro, L., Hen-Shoval, D., Hazut, N., Rapps, K., Dar, S., Zalsman, G., Mechoulam, R., Weller, A., & Shoval, G. (2018) · Physiology & Behavior · doi:10.1016/j.physbeh.2018.12.019 · Cited by 76 · see citing works

Cannabidiol effects in the prepulse inhibition disruption induced by amphetamine

Pedrazzi, J. F. C., Issy, A. C., Gomes, F. V., Guimarães, F. S., & Del-Bel, E. A. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3945-7 · Cited by 76 · see citing works

Cannabidiol Modulates Fear Memory Formation Through Interactions with Serotonergic Transmission in the Mesolimbic System

Norris, C., Loureiro, M., Kramar, C. P., Zunder, J. S., Renard, J., Rushlow, W. J., & Laviolette, S. R. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.93 · Cited by 75 · see citing works

Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis

O’Neill, A., Wilson, R. P., Blest‐Hopley, G., Annibale, L., Colizzi, M., Brammer, M. J., Giampietro, V., & Bhattacharyya, S. (2020) · Psychological Medicine · doi:10.1017/s0033291719003519 · Cited by 75 · see citing works

A Phase I, Open Label, Four-Way Crossover Study to Compare the Pharmacokinetic Profiles of a Single Dose of 20 mg of a Cannabis Based Medicine Extract (CBME) Administered on 3 Different Areas of the Buccal Mucosa and to Investigate the Pharmacokinetics of CBMEper Oralin Healthy Male and Female Volunteers (GWPK0112)

Guy, G. W., & Robson, P. (2004) · Journal of Cannabis Therapeutics · doi:10.1300/j175v03n04_01 · Cited by 73 · see citing works

Neural correlates of interactions between cannabidiol and Δ 9 ‐tetrahydrocannabinol in mice: implications for medical cannabis

Todd, S. M., & Arnold, J. C. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13333 · Cited by 72 · see citing works

Comparative metabolism of cannabidiol in dog, rat and man

Harvey, D. J., Samara, E. E., & Mechoulam, R. (1991) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(91)90358-9 · Cited by 71 · see citing works

The effects of cannabidiol on persecutory ideation and anxiety in a high trait paranoid group

Hundal, H., Lister, R., Evans, N., Antley, A., Englund, A., Murray, R. M., Freeman, D. H., & Morrison, P. D. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117737400 · Cited by 70 · see citing works

Effects of intra-infralimbic prefrontal cortex injections of cannabidiol in the modulation of emotional behaviors in rats: Contribution of 5HT1A receptors and stressful experiences

Marinho, A. L. Z., Vila-Verde, C., Fogaça, M. V., & Guimarães, F. S. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.02.023 · Cited by 68 · see citing works

Developmental regulation of fear learning and anxiety behavior by endocannabinoids

Lee, T. T.-Y., Hill, M. N., & Lee, F. S. (2015) · Genes Brain & Behavior · doi:10.1111/gbb.12253 · Cited by 67 · see citing works

Cannabidiol reverses the mCPP ‐induced increase in marble‐burying behavior

Nardo, M., Casarotto, P. C., Gomes, F. V., & Guimarães, F. S. (2013) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12051 · Cited by 65 · see citing works

Buspirone: Back to the Future

Howland, R. H. (2015) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20151022-01 · Cited by 65 · see citing works

Comparative effectiveness of continuation and maintenance treatments for persistent depressive disorder in adults

Machmutow, K., Meister, R., Jansen, A., Kriston, L., Watzke, B., Härter, M. C., & Liebherz, S. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012855.pub2 · Cited by 64 · see citing works

Cannabidiol attenuates insular dysfunction during motivational salience processing in subjects at clinical high risk for psychosis

Wilson, R. P., Bossong, M. G., Appiah‐Kusi, E., Petros, N., Brammer, M. J., Pérez, J., Allen, P., McGuire, P. K., & Bhattacharyya, S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0534-2 · Cited by 64 · see citing works

The novel cannabinoid receptor GPR55 mediates anxiolytic-like effects in the medial orbital cortex of mice with acute stress

Shi, Q., Yang, L.-K., Shi, W., Wang, L., Zhou, S., Guan, S., Zhao, M., & Yang, Q. (2017) · Molecular Brain · doi:10.1186/s13041-017-0318-7 · Cited by 61 · see citing works

CBD modulates DNA methylation in the prefrontal cortex and hippocampus of mice exposed to forced swim

Sales, A. J., Guimarães, F. S., & Joca, S. R. L. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112627 · Cited by 58 · see citing works

Prolonged Cannabidiol Treatment Lacks on Detrimental Effects on Memory, Motor Performance and Anxiety in C57BL/6J Mice

Schleicher, E. M., Ott, F. W., Müller, M., Silcher, B., Sichler, M. E., Löw, M. J., Wagner, J. M., & Bouter, Y. (2019) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2019.00094 · Cited by 57 · see citing works

The Divergent Effects of CDPPB and Cannabidiol on Fear Extinction and Anxiety in a Predator Scent Stress Model of PTSD in Rats

Shallcross, J., Hámor, P. U., Bechard, A. R., Romano, M., Knackstedt, L. A., & Schwendt, M. (2019) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2019.00091 · Cited by 57 · see citing works

The role of 5-HT 1A receptors in the anti-aversive effects of cannabidiol on panic attack-like behaviors evoked in the presence of the wild snake Epicrates cenchria crassus (Reptilia, Boidae)

Twardowschy, A., Castiblanco-Urbina, M. A., Uribe-Mariño, A., Biagioni, A. F., Salgado-Rohner, C. J., Crippa, J. A. S., & Coimbra, N. C. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113493363 · Cited by 56 · see citing works

Effects of intracisternal administration of cannabidiol on the cardiovascular and behavioral responses to acute restraint stress

Granjeiro, É. M., Gomes, F. V., Guimarães, F. S., Corrêa, F. M. D. A., & Resstel, L. B. M. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.06.027 · Cited by 55 · see citing works

Cannabidiol (CBD) enhances lipopolysaccharide (LPS)-induced pulmonary inflammation in C57BL/6 mice

Karmaus, P. W. F., Wagner, J. G., Harkema, J. R., Kaminski, N. E., & Kaplan, B. L. F. (2012) · Journal of Immunotoxicology · doi:10.3109/1547691x.2012.741628 · Cited by 54 · see citing works

Central administration of GPR 55 receptor agonist and antagonist modulates anxiety‐related behaviors in rats

Rahimi, A., Moghaddam, A. H., & Roohbakhsh, A. (2015) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12099 · Cited by 53 · see citing works

Effect of cannabidiol on endocannabinoid, glutamatergic and GABAergic signalling markers in male offspring of a maternal immune activation (poly I:C) model relevant to schizophrenia

Osborne, A. L., Solowij, N., Babic, I., Lum, J. S., Newell, K. A., Huang, X., & Weston–Green, K. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109666 · Cited by 53 · see citing works

Phytocannabinoids

Kobayashi, J., Gibbons, S., Falk, H., & Kinghorn, A. D. (2017) · Fortschritte der Chemie Organischer Naturstoffe/Fortschritte der Chemie organischer Naturstoffe/Progress in the chemistry of organic natural products · doi:10.1007/978-3-319-45541-9 · Cited by 53 · see citing works

Pharmacological and non-pharmacological treatments for major depressive disorder in adults: A systematic review and network meta-analysis

Chen, C., & Shan, W. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.112595 · Cited by 51 · see citing works

Resilience Dysregulation in Major Depressive Disorder: Focus on Glutamatergic Imbalance and Microglial Activation

Réus, G. Z., de Moura, A. B., da Silva, R. H., Resende, W. R., & Quevedo, J. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170630164715 · Cited by 50 · see citing works

Neuroprotection and reduction of glial reaction by cannabidiol treatment after sciatic nerve transection in neonatal rats

Perez, M., Ulian-Benitez, S., Cartarozzi, L. P., Bel, E. A. D., Guimarães, F. S., & de Oliveira, A. L. R. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12341 · Cited by 49 · see citing works

Couple therapy for depression

Barbato, A., D’Avanzo, B., & Parabiaghi, A. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004188.pub3 · Cited by 48 · see citing works

Procognitive Effects of Antidepressants and Other Therapeutic Agents in Major Depressive Disorder: A Systematic Review.

Blumberg, M., Vaccarino, S., & McInerney, S. (2020) · Journal of Clinical Psychiatry · doi:10.4088/jcp.19r13200 · Cited by 48 · see citing works

Endocannabinoid system: Potential novel targets for treatment of schizophrenia

Saito, A., Ballinger, M. D., Pletnikov, M. V., Wong, D. F., & Kamiya, A. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.11.020 · Cited by 47 · see citing works

Endocannabinoid signaling in psychiatric disorders: a review of positron emission tomography studies

Sloan, M. E., Grant, C. W., Gowin, J. L., Ramchandani, V. A., & Foll, B. L. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0081-z · Cited by 47 · see citing works

Decreased sensitivity in adolescent versus adult rats to the antidepressant-like effects of cannabidiol

Bis‐Humbert, C., García‐Cabrerizo, R., & García-Fuster, M. J. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05481-4 · Cited by 45 · see citing works

MK-801-induced deficits in social recognition in rats

Deiana, S., Watanabe, A., Yamasaki, Y., Amada, N., Kikuchi, T., Stott, C. G., & Riedel, G. (2015) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000178 · Cited by 44 · see citing works

Cannabidiol regulates the expression of hypothalamus-pituitary-adrenal axis-related genes in response to acute restraint stress

Viudez‐Martínez, A., García‐Gutiérrez, M. S., & Manzanares, J. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118805495 · Cited by 43 · see citing works

Cannabidiol disrupts conditioned fear expression and cannabidiolic acid reduces trauma-induced anxiety-related behaviour in mice

Assareh, N., Gururajan, A., Zhou, C., Luo, J. L., Kevin, R. C., & Arnold, J. C. (2020) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000565 · Cited by 40 · see citing works

A time‐dependent contribution of hippocampal CB1, CB2 and PPARγ receptors to cannabidiol‐induced disruption of fear memory consolidation

Raymundi, A. M., da Silva, T. R., Zampronio, A. R., Guimarães, F. S., Bertoglio, L. J., & Stern, C. A. J. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14895 · Cited by 39 · see citing works

Effects on variable-interval performance in rats of delta 9-tetrahydrocannabinol and cannabidiol, separately and in combination.

Zuardi, A. W., & Karniol, I. G. (1983) · PubMed · Cited by 38 · see citing works

Interactions between cannabidiol and Δ9-THC following acute and repeated dosing: Rebound hyperactivity, sensorimotor gating and epigenetic and neuroadaptive changes in the mesolimbic pathway

Todd, S. M., Zhou, C., Clarke, D. J., Chohan, T. W., Bahceci, D., & Arnold, J. C. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.12.004 · Cited by 38 · see citing works

The classification of depression: are we still confused?

Cole, J. H., McGuffin, P., & FARMER, A. E. (2008) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.107.039826 · Cited by 37 · see citing works

An update on current treatment strategies and emerging agents for the management of schizophrenia

Maroney, M. E. (2020) · The American Journal of Managed Care · doi:10.37765/ajmc.2020.43012 · Cited by 37 · see citing works

Tracking the impact of translational research in psychiatry: state of the art and perspectives

Machado‐Vieira, R. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-175 · Cited by 36 · see citing works

Comparative effects between cannabidiol and diazepam on neophobia food intake and conflict behavior

Filho, N. G. S., & Tufik, S. B. (1981) · Research communications in psychology, psychiatry and behavior · Cited by 36 · see citing works

Epigenetic regulation in major depression and other stress-related disorders: molecular mechanisms, clinical relevance and therapeutic potential

Yuan, M., Yang, B., Rothschild, G., Mann, J. J., Sanford, L. D., Tang, X., Huang, C., Wang, C., & Zhang, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01519-z · Cited by 246 · see citing works

Cannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain

Stella, B., Baratta, F., Pepa, C. D., Arpicco, S., Gastaldi, D., & Dosio, F. (2021) · Drugs · doi:10.1007/s40265-021-01579-x · Cited by 171 · see citing works

Promising Nanocarriers to Enhance Solubility and Bioavailability of Cannabidiol for a Plethora of Therapeutic Opportunities

Grifoni, L., Vanti, G., Donato, R., Sacco, C., & Bilia, A. R. (2022) · Molecules · doi:10.3390/molecules27186070 · Cited by 118 · see citing works

Latest updates on the serotonergic system in depression and anxiety

Lin, J., Liu, W., Guan, J., Cui, J.-N., Shi, R.-L., Wang, L., Chen, D., & Liu, Y. (2023) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2023.1124112 · Cited by 88 · see citing works

Citrus limon L. (lemon) seed extract shows neuro-modulatory activity in an in vivo thiopental-sodium sleep model by reducing the sleep onset and enhancing the sleep duration

Rahman, M. M., Islam, F., Parvez, A., Azad, A., Ashraf, G. M., Ullah, M. F., & Ahmed, M. (2022) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2101042 · Cited by 76 · see citing works

Pro-Inflammatory Cytokines: Potential Links between the Endocannabinoid System and the Kynurenine Pathway in Depression

Zádor, F., Joca, S. R. L., Nagy-Grócz, G., Dvorácskó, S., Szűcs, E., Tömböly, C., Benyhe, S., & Vécsei, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115903 · Cited by 71 · see citing works

An Overview of Cannabidiol as a Multifunctional Drug: Pharmacokinetics and Cellular Effects

Naya, N. M., Kelly, J., Corna, G., Golino, M., Polizio, A. H., Abbate, A., Toldo, S. A., & Mezzaroma, E. (2024) · Molecules · doi:10.3390/molecules29020473 · Cited by 73 · see citing works

Delivering therapeutic cannabinoids via skin: Current state and future perspectives

Tijani, A. O., Thakur, D., Mishra, D., Frempong, D., Chukwunyere, U. I., & Puri, A. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.05.005 · Cited by 66 · see citing works

Intracellular Molecular Targets and Signaling Pathways Involved in Antioxidative and Neuroprotective Effects of Cannabinoids in Neurodegenerative Conditions

Tadijan, A., Vlašić, I., Vlainić, J., Đikić, D., Oršolić, N., & Jembrek, M. J. (2022) · Antioxidants · doi:10.3390/antiox11102049 · Cited by 64 · see citing works

Emerging Therapeutic Potential of Cannabidiol (CBD) in Neurological Disorders: A Comprehensive Review

Singh, K., Bhushan, B., Chanchal, D. K., Sharma, S. K., Rani, K., Yadav, M. K., Porwal, P., Kumar, S., Sharma, A., Virmani, T., et al. (2023) · Behavioural Neurology · doi:10.1155/2023/8825358 · Cited by 64 · see citing works

Neuropharmacological and Antidiabetic Potential of Lannea coromandelica (Houtt.) Merr. Leaves Extract: An Experimental Analysis

Islam, F., Mitra, S., Nafady, M. H., Rahman, M. T., Tirth, V., Akter, A., Emran, T. B., Mohamed, A. A.-R., Algahtani, A., & El-Kholy, S. S. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/6144733 · Cited by 63 · see citing works

Improved Bioavailability with Dry Powder Cannabidiol Inhalation: A Phase 1 Clinical Study

Devinsky, O., Kraft, K. S., Rusch, L. M., Fein, M., & Leone‐Bay, A. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.08.012 · Cited by 62 · see citing works

Cannabinoid Therapeutics in Chronic Neuropathic Pain: From Animal Research to Human Treatment

Campos, R. M. P., Aguiar, A. F. L., Paes-Colli, Y., Trindade, P. M. P., Ferreira, B. K., Reis, R. A. D. M., & Sampaio, L. D. S. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.785176 · Cited by 59 · see citing works

The therapeutic potential of purified cannabidiol

O’Sullivan, S. E., Jensen, S. S., Nikolajsen, G. N., Bruun, H. Z., Bhuller, R., & Hoeng, J. (2023) · Journal of Cannabis Research · doi:10.1186/s42238-023-00186-9 · Cited by 56 · see citing works

Neuroinflammation and neuroprogression in depression: Effects of alternative drug treatments

Richardson, B., MacPherson, A., & Bambico, F. R. (2022) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2022.100554 · Cited by 56 · see citing works

Neuropharmacological Effects of Terpenoids on Preclinical Animal Models of Psychiatric Disorders: A Review

Mony, T. J., Elahi, F., Choi, J. W., & Park, S. J. (2022) · Antioxidants · doi:10.3390/antiox11091834 · Cited by 56 · see citing works

Down and High: Reflections Regarding Depression and Cannabis

Langlois, C. C., Potvin, S., Khullar, A., & Tourjman, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.625158 · Cited by 52 · see citing works

Clinical outcome data of anxiety patients treated with cannabis-based medicinal products in the United Kingdom: a cohort study from the UK Medical Cannabis Registry

Rifkin-Zybutz, R. P., Erridge, S., Holvey, C., Coomber, R., Gaffney, J., Lawn, W., Barros, D. A. R., Bhoskar, U., Mwimba, G., Praveen, K., et al. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06399-3 · Cited by 52 · see citing works

An overview on synthetic and biological activities of cannabidiol (CBD) and its derivatives

Wang, X., Zhang, H., Liu, Y., Yang, X., Yang, B., Li, H., & Chen, L. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106810 · Cited by 57 · see citing works

Cannabinoid CB1 Receptor Involvement in the Actions of CBD on Anxiety and Coping Behaviors in Mice

Austrich-Olivares, A., García‐Gutiérrez, M. S., Illescas, L., Gasparyan, A., & Manzanares, J. (2022) · Pharmaceuticals · doi:10.3390/ph15040473 · Cited by 49 · see citing works

A Review of Ocular Complications Associated with Medications Used for Anxiety, Depression, and Stress

Constable, P. A., Al-Dasooqi, D., Bruce, R., & Senthil, M. P. (2022) · Clinical Optometry · doi:10.2147/opto.s355091 · Cited by 48 · see citing works

Citalopram and Cannabidiol

Anderson, L. L., Doohan, P. T., Oldfield, L., Kevin, R. C., Arnold, J. C., Berger, M., Amminger, G. P., & McGregor, I. S. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001427 · Cited by 48 · see citing works

Selected Seeds as Sources of Bioactive Compounds with Diverse Biological Activities

Sławińska, N., & Olas, B. (2022) · Nutrients · doi:10.3390/nu15010187 · Cited by 50 · see citing works

Cannabidiol for the Treatment of Brain Disorders: Therapeutic Potential and Routes of Administration

Yau, G. T. Y., Tai, W., Arnold, J. C., Chan, H., & Kwok, P. C. L. (2023) · Pharmaceutical Research · doi:10.1007/s11095-023-03469-1 · Cited by 46 · see citing works

Immunomodulatory Role of CB2 Receptors in Emotional and Cognitive Disorders

Morcuende, Á., García‐Gutiérrez, M. S., Tambaro, S., Nieto, E. O., Manzanares, J., & Femenía, T. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.866052 · Cited by 44 · see citing works

Miswiring the brain: Human prenatal Δ9-tetrahydrocannabinol use associated with altered fetal hippocampal brain network connectivity

Thomason, M. E., Palopoli, A. C., Jariwala, N. N., Werchan, D. M., Chen, A., Adhikari, S., Espinoza‐Heredia, C., Brito, N. H., & Trentacosta, C. J. (2021) · Developmental Cognitive Neuroscience · doi:10.1016/j.dcn.2021.101000 · Cited by 42 · see citing works

Modulation of Endocannabinoid System Components in Depression: Pre-Clinical and Clinical Evidence

Bright, U., & Akirav, I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105526 · Cited by 47 · see citing works

Sex-dependent differences in the anxiolytic-like effect of cannabidiol in the elevated plus-maze

Fabris, D., Carvalho, M. C., Brandão, M., Prado, W. A., Zuardi, A., Crippa, J., de Oliveira, A. D., Lovick, T., & Genaro, K. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221125440 · Cited by 38 · see citing works

THC, CBD, and Anxiety: a Review of Recent Findings on the Anxiolytic and Anxiogenic Effects of Cannabis’ Primary Cannabinoids

Lichenstein, S. D. (2022) · Current Addiction Reports · doi:10.1007/s40429-022-00450-7 · Cited by 38 · see citing works

Cannabinoids as Immune System Modulators: Cannabidiol Potential Therapeutic Approaches and Limitations

Aziz, A.-I., Nguyen, L. C., Oumeslakht, L., Bensussan, A., & Mkaddem, S. B. (2022) · Cannabis and Cannabinoid Research · doi:10.1089/can.2022.0133 · Cited by 40 · see citing works

Phytocannabinoids and schizophrenia: Focus on adolescence as a critical window of enhanced vulnerability and opportunity for treatment

Štark, T., Martino, S. D., Drago, F., Wotjak, C. T., & Micale, V. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105938 · Cited by 37 · see citing works

Exploring the Role of Nutraceuticals in Major Depressive Disorder (MDD): Rationale, State of the Art and Future Prospects

Álvarez-Mon, M. Á., Ortega, M. A., Montero, C. G., Fraile‐Μartinez, O., Monserrat, J., Lahera, G., Mora, F., Rodríguez-Quiroga, A., Fernández-Rojo, S., Quintero, J., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14080821 · Cited by 36 · see citing works

Sex Differences in the Neuropsychiatric Effects and Pharmacokinetics of Cannabidiol: A Scoping Review

Matheson, J., Bourgault, Z., & Foll, B. L. (2022) · Biomolecules · doi:10.3390/biom12101462 · Cited by 37 · see citing works

Anti-Inflammatory and Antiviral Effects of Cannabinoids in Inhibiting and Preventing SARS-CoV-2 Infection

Janecki, M., Graczyk, M., Lewandowska, A. A., & Pawlak, Ł. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084170 · Cited by 33 · see citing works

Exploring pharmacological options for adolescent depression: a preclinical evaluation with a sex perspective

Ledesma‐Corvi, S., Hernández‐Hernández, E., & García-Fuster, M. J. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01994-y · Cited by 33 · see citing works

Development of Stimuli-Responsive Chitosan/ZnO NPs Transdermal Systems for Controlled Cannabidiol Delivery

Radwan-Pragłowska, J., Janus, Ł., Piątkowski, M., Sierakowska, A., Szajna, E., Matýsek, D., & Bogdał, D. (2021) · Polymers · doi:10.3390/polym13020211 · Cited by 31 · see citing works

Alternative Therapy of Psychosis: Potential Phytochemicals and Drug Targets in the Management of Schizophrenia

Saleem, A., Qurat-ul-Ain, Q.-U.-A., & Akhtar, M. F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.895668 · Cited by 31 · see citing works

Pharmacological strategies for post-traumatic stress disorder (PTSD): From animal to clinical studies

Gasparyan, A., Navarro, D., Navarrete, F., & Manzanares, J. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109211 · Cited by 32 · see citing works

Cannabidiol and neurodegeneration: From molecular mechanisms to clinical benefits

Jha, S. K., Nelson, V. K., Suryadevara, P. R., Panda, S. P., Pullaiah, C. P., Nuli, M. V., Kamal, M., Imran, M., Ausali, S., Abomughaid, M. M., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102386 · Cited by 30 · see citing works

CBD-Loaded Nanostructured Lipid Carriers: Optimization, Characterization, and Stability

Xie, Y., Li, P., Fu, D., Yang, F., Sui, X., Huang, B., Liu, J., & Chi, J. (2024) · ACS Omega · doi:10.1021/acsomega.4c04771 · Cited by 29 · see citing works

Effects of rich cannabidiol oil on behavioral disturbances in patients with dementia: A placebo controlled randomized clinical trial

Hermush, V., Ore, L., Stern, N., Mizrahi, N., Fried, M., Krivoshey, M., Staghon, E., Lederman, V. E., & Schleider, L. B. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.951889 · Cited by 33 · see citing works

Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150 mg/mL) versus placebo in mild to moderate anxiety subjects: A double blind multicenter randomized clinical trial

Gundugurti, P. R., Banda, N., Yadlapalli, S. S. R., Narala, A., Thatikonda, R., Kocherlakota, C., & Kothapalli, K. S. D. (2024) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2024.104073 · Cited by 27 · see citing works

Acute objective and subjective intoxication effects of legal-market high potency THC-dominant versus CBD-dominant cannabis concentrates

Drennan, M. L., Karoly, H. C., Bryan, A. D., Hutchison, K. E., & Bidwell, L. C. (2021) · Scientific Reports · doi:10.1038/s41598-021-01128-2 · Cited by 27 · see citing works

Medicinal Cannabis and Central Nervous System Disorders

Ortiz, Y. T., McMahon, L. R., & Wilkerson, J. L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.881810 · Cited by 27 · see citing works

Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatment

Palumbo, J., Thomas, B. F., Budimirovic, D. B., Siegel, S. J., Tassone, F., Hagerman, R. J., Faulk, C. D., O’Quinn, S., & Sebree, T. B. (2023) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-023-09475-z · Cited by 27 · see citing works

Efficacy of cannabinoids in neurodevelopmental and neuropsychiatric disorders among children and adolescents: a systematic review

Rice, L. J., Cannon, L., Dadlani, N., Cheung, M. M. Y., Einfeld, S., Efron, D., Dossetor, D. R., & Elliott, E. J. (2023) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-023-02169-w · Cited by 27 · see citing works

Differences in the Perception of Dietary Supplements between Dietary Supplement/Medicine Users and Non-Users

Chiba, T., & Tanemura, N. (2022) · Nutrients · doi:10.3390/nu14194114 · Cited by 26 · see citing works

Acute and Extended Anxiolytic Effects of Cannabidiol in Cannabis Flower: A Quasi-Experimental ad libitum Use Study

Bidwell, L. C., Martin‐Willett, R., Skrzynski, C. J., Lisano, J. K., Torres, M. O., Giordano, G., Hutchison, K. E., & Bryan, A. D. (2024) · Cannabis and Cannabinoid Research · doi:10.1089/can.2023.0187 · Cited by 26 · see citing works

Investigation of Potential Antioxidant, Thrombolytic and Neuropharmacological Activities of Homalomena aromatica Leaves Using Experimental and In Silico Approaches

Ali, M. S., Sayem, S. A. J., Habibullah, Quah, Y., Lee, E., Birhanu, B. T., Suk, K., & Park, S. (2021) · Molecules · doi:10.3390/molecules26040975 · Cited by 26 · see citing works

Cannabidiol and Beta-Caryophyllene in Combination: A Therapeutic Functional Interaction

Blanton, H. L., Yin, L., Duong, J., & Benamar, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415470 · Cited by 26 · see citing works

Cannabidiol Intervention for Muscular Tension, Pain, and Sleep Bruxism Intensity—A Randomized, Double-Blind Clinical Trial

Walczyńska-Dragon, K., Kurek-Górecka, A. M., Niemczyk, W., Nowak, Z., Baron, S., Olczyk, P., Nitecka-Buchta, A., & Kempa, W. M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051417 · Cited by 26 · see citing works

Health Benefits of Functional Foods

Jurek, J. M. (2022) · Journal of Biomedical Research & Environmental Sciences · doi:10.37871/jbres1598 · Cited by 31 · see citing works

Tryptophan metabolism in health and disease- implications for non-communicable diseases

Gabela, A. M., Mthembu, N., & Hadebe, S. (2025) · Immunology Letters · doi:10.1016/j.imlet.2025.107093 · Cited by 29 · see citing works

Cannabinoids and sleep-wake cycle: The potential role of serotonin

Vaseghi, S., Arjmandi-Rad, S., Nasehi, M., & Zarrindast, M. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113440 · Cited by 24 · see citing works

Eight Weeks of Daily Cannabidiol Supplementation Improves Sleep Quality and Immune Cell Cytotoxicity

Kisiolek, J. N., Flores, V. A., Ramani, A. H., Butler, B., Haughian, J. M., & Stewart, L. K. (2023) · Nutrients · doi:10.3390/nu15194173 · Cited by 25 · see citing works

Development of cannabidiol derivatives as potent broad-spectrum antibacterial agents with membrane-disruptive mechanism

Fang, S., Kang, W.-T., Li, H., Cai, Q., Liang, W., Zeng, M., Yu, Q., Zhong, R., Tao, Y., Liu, S., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116149 · Cited by 24 · see citing works

Novel rapid treatment options for adolescent depression

Ledesma‐Corvi, S., Jornet-Plaza, J., Gálvez‐Melero, L., & García-Fuster, M. J. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107085 · Cited by 22 · see citing works

Peculiarities of meroterpenoids and their bioproduction

Han, J., Jiang, L., Zhang, L., Quinn, R. J., Liu, X., & Feng, Y. (2021) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-021-11312-z · Cited by 23 · see citing works

Comparison between cannabidiol and sertraline for the modulation of post-traumatic stress disorder-like behaviors and fear memory in mice

Han, X., Song, X., Song, D., Xie, G., Guo, H., Wu, N., & Li, J. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06132-6 · Cited by 24 · see citing works

CBD enhances the cognitive score of adolescent rats prenatally exposed to THC and fine-tunes relevant effectors of hippocampal plasticity

Castelli, V., Lavanco, G., D’Amico, C., Feo, S., Tringali, G., Kuchař, M., Cannizzaro, C., & Brancato, A. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1237485 · Cited by 23 · see citing works

Cannabidiol in Foods and Food Supplements: Evaluation of Health Risks and Health Claims

Engeli, B. E., Lachenmeier, D. W., Diel, P. R., Guth, S., Villar-Fernandez, M., Roth, A., Lampen, A., Cartus, A. T., Wätjen, W., Hengstler, J. G., et al. (2025) · Nutrients · doi:10.3390/nu17030489 · Cited by 22 · see citing works

Possible actions of cannabidiol in obsessive-compulsive disorder by targeting the WNT/β-catenin pathway

Vallée, A., Lecarpentier, Y., & Vallée, J.-N. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01086-1 · Cited by 22 · see citing works

The Use of Cannabidiol as a Novel Treatment for Oral Stereotypic Behaviour (Crib-Biting) in a Horse

Cunha, R. Z., Felisardo, L. L., Salamanca, G., Marchioni, G. G., Neto, O. I., & Chiocchetti, R. (2022) · Veterinary and Animal Science · doi:10.1016/j.vas.2023.100289 · Cited by 22 · see citing works

Cannabidiol (CBD) in the Self-Treatment of Depression-Exploratory Study and a New Phenomenon of Concern for Psychiatrists

Więckiewicz, G., Stokłosa, I., Stokłosa, M., Gorczyca, P. W., & Pudło, R. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.837946 · Cited by 21 · see citing works

Pharmacokinetics of Cannabidiol in Sprague-Dawley Rats After Oral and Pulmonary Administration

Schwotzer, D., Kulpa, J., Trexler, K. R., Dye, W. W., Jantzi, J., Irshad, H., Ware, M. A., Bonn‐Miller, M. O., McDonald, J. D., & Lefever, T. (2022) · Cannabis and Cannabinoid Research · doi:10.1089/can.2022.0121 · Cited by 21 · see citing works

Antidepressant-like effects of cannabidiol in a rat model of early-life stress with or without adolescent cocaine exposure

Bis‐Humbert, C., García‐Cabrerizo, R., & García-Fuster, M. J. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00285-5 · Cited by 20 · see citing works

Adjunctive Management of Opioid Withdrawal with the Nonopioid Medication Cannabidiol

Kudrich, C., Hurd, Y. L., Salsitz, E. A., & Wang, A. (2021) · Cannabis and Cannabinoid Research · doi:10.1089/can.2021.0089 · Cited by 21 · see citing works

The NLRP3 Inflammasome in Stress Response: Another Target for the Promiscuous Cannabidiol

dos Santos, A. H., Vila-Verde, C., Guimarães, F. S., Joca, S. R. L., & Lisboa, S. F. D. S. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220411101217 · Cited by 20 · see citing works

Shared genetic architecture highlights the bidirectional association between major depressive disorder and fracture risk

Zhao, P., Ying, Z., Yuan, C., Zhang, H., Dong, A., Tao, J., Yi, X., Yang, M., Jin, W., Tian, W., et al. (2024) · General Psychiatry · doi:10.1136/gpsych-2023-101418 · Cited by 19 · see citing works

Cannabidiol–loaded biomimetic macrophage membrane vesicles against post–traumatic stress disorder assisted by ultrasound

Li, Q., Wang, C., Hu, J., Jiao, W., Tang, Z., Song, X., Wu, Y., Dai, J., Gao, P., Du, L., et al. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.122872 · Cited by 19 · see citing works

Endocannabinoid signaling and epigenetics modifications in the neurobiology of stress-related disorders

Coelho, A. A., Bastos, S., Gobira, P. H., & Lisboa, S. F. D. S. (2023) · Neuronal Signaling · doi:10.1042/ns20220034 · Cited by 22 · see citing works

Development and Evaluation of Cannabidiol Orodispersible Tablets Using a 23-Factorial Design

Vlad, R., Antonoaea, P., Todoran, N., Rédai, E., Bîrsan, M., Muntean, D., Imre, S., Hancu, G., Farczádi, L., & Ciurba, A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071467 · Cited by 18 · see citing works

Advances and Challenges of Cannabidiol as an Anti-Seizure Strategy: Preclinical Evidence

Zavala‐Tecuapetla, C., Luna‐Munguía, H., López‐Meraz, M. L., & Cuéllar‐Herrera, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232416181 · Cited by 19 · see citing works

Analysis of influencing factors of anxiety and depression in maintenance hemodialysis patients and its correlation with BDNF, NT-3 and 5-HT levels

Peng, X., Feng, S.-J., Zhang, P., Sang, S., & Zhang, Y. (2023) · PeerJ · doi:10.7717/peerj.16068 · Cited by 17 · see citing works

A cohort study comparing the effects of medical cannabis for anxiety patients with and without comorbid sleep disturbance

Murphy, M., Erridge, S., Holvey, C., Coomber, R., Rucker, J., & Sodergren, M. H. (2023) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12407 · Cited by 17 · see citing works

Cannabidiol and Other Cannabinoids in Demyelinating Diseases

Navarrete, C. M., García‐Martín, A., Rolland, A. P., DeMesa, J., & Muñóz, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062992 · Cited by 19 · see citing works

Vitiligo and Mental Health: Natural Compounds’ Usefulness

Bartolomeo, L. D., Custurone, P., Irrera, N., Borgia, F., Vaccaro, F., Squadrito, F., & Vaccaro, M. (2023) · Antioxidants · doi:10.3390/antiox12010176 · Cited by 18 · see citing works

Cannabidiol protects the liver from α-Amanitin-induced apoptosis and oxidative stress through the regulation of Nrf2

Wang, H., Yang, G., Zhang, X., Zhang, H., Liu, Y., Wang, C., Miao, L., Li, Y., Huang, Y., Teng, H., et al. (2023) · Food and Chemical Toxicology · doi:10.1016/j.fct.2023.114196 · Cited by 17 · see citing works

Therapeutic potential of cannabidiol (CBD) in the treatment of cardiovascular diseases

Naya, N. M., Kelly, J., Hogwood, A. C., Abbate, A., & Toldo, S. A. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2351513 · Cited by 19 · see citing works

Dose-Dependent Antidepressant-Like Effects of Cannabidiol in Aged Rats

Hernández‐Hernández, E., & García-Fuster, M. J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.891842 · Cited by 16 · see citing works

Cannabidiol—A friend or a foe?

Tihăuan, B.-M., Onisei, T., Slootweg, W., Gună, D., Iliescu, C., & Chifiriuc, M. C. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107036 · Cited by 16 · see citing works

ESTUDO ANATOMOPATOLÓGICO DO IMPACTO DAS LESÕES CAUSADAS PELA Dirofilaria immitis EM FELINOS: UMA REVISÃO DE LITERATURA

de Oliveira, L. C., Holanda, M. M. V., Santos, M., Teles, A. V. D. A., Farias, T. C., Rodrigues, K. C., de Almeida, M. C., Filgueiras, J. R. S. R., Rocha, G. D. S., Silva, F. M. D. O. E., et al. (2025) · Editora In Vivo eBooks · doi:10.47242/978-65-87959-74-0-9 · Cited by 15 · see citing works

TRATAMENTO CIRÚRGICO E ADJUVANTE DAS NEOPLASIAS MAMÁRIAS EM CADELAS

Pinheiro, G. C., Felix, J. P. D. S., de Pina, S. S., Amaral, L. I. R., Almeida, M. E. D. R., Filgueiras, J. R. S. R., Trindade, L. C. B., de Castro, K. K. R., Rocha, G. D. S., Esteves, M. J. B., et al. (2025) · Editora In Vivo eBooks · doi:10.47242/978-65-87959-74-0-12 · Cited by 15 · see citing works

DIABETES MELLITUS EM CÃES: UMA ABORDAGEM TERAPÊUTICA

do Amaral, C. C., Passos, E. G., Guedes, R. F. D. M., Silva, F. M. D. O. E., Bezerra, B. M. O., Cortez, A. A., Chaves, R. N., Santos, B. M. B., Rondon, F. C. M., & Cruz, C. E. B. (2025) · Editora In Vivo eBooks · doi:10.47242/978-65-87959-74-0-14 · Cited by 15 · see citing works

Zebrafish as an Animal Model in Cannabinoid Research

Lachowicz, J. I., Szopa, A., Ignatiuk, K., Świąder, K., & Serefko, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310455 · Cited by 15 · see citing works

How “K-Style” has influenced the younger generation through local Vietnamese influencers

Kim, H., & Choo, H. J. (2023) · Fashion and Textiles · doi:10.1186/s40691-023-00359-3 · Cited by 17 · see citing works

Therapeutic potential of minor cannabinoids in psychiatric disorders: A systematic review

Cammà, G., Verdouw, M. P., van der Meer, P. B., Groenink, L., & Batalla, A. (2024) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.10.006 · Cited by 16 · see citing works

Cannabidiol prevents lipopolysaccharide-induced sickness behavior and alters cytokine and neurotrophic factor levels in the brain

Tito, P. A. L., Bernardino, T. C. D. S., Bellozi, P. M. Q., da Silva, M. C. M., de Miranda, A. S., Vieira, É. L. M., Moreira, F. A., Palotás, A., de Oliveira, A. C. P., & Reis, H. J. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00301-8 · Cited by 15 · see citing works

Cannabis consumption and prosociality

Vigil, J. M., Stith, S. S., & Chanel, T. (2022) · Scientific Reports · doi:10.1038/s41598-022-12202-8 · Cited by 15 · see citing works

A reliable quantitative method for determining CBD content and release from transdermal patches in Franz cells

Yu, L., Madsen, F. B., Eriksen, S. H., Andersen, A. J. C., & Skov, A. L. (2022) · Phytochemical Analysis · doi:10.1002/pca.3188 · Cited by 15 · see citing works

Spinal Glia-Driven Neuroinflammation as a Therapeutic Target for Neuropathic Pain: Rational Development of Novel Analgesics.

Zhang, Z.-H., Niu, Z.-Y., & Dong, S.-L. (2025) · Neuroscience and Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106404 · Cited by 16 · see citing works

The effects of cannabidiol and Δ9-tetrahydrocannabinol, alone and in combination, in the maximal electroshock seizure model

Dlugosz, L., Zhou, H. Z., Scott, B. W., & Burnham, W. M. (2023) · Epilepsy Research · doi:10.1016/j.eplepsyres.2023.107087 · Cited by 14 · see citing works

Enhancing transmucosal delivery of CBD through nanoemulsion: in vitro and in vivo studies

Provenzano, R., Caro, C. D., Vitiello, A., Izzo, L., Ritieni, A., Ungaro, F., Quaglia, F., Russo, E., Miro, A., & d’Angelo, I. (2023) · Drug Delivery and Translational Research · doi:10.1007/s13346-023-01481-x · Cited by 14 · see citing works

An In Silico Study for Expanding the Utility of Cannabidiol in Alzheimer’s Disease Therapeutic Development

Choi, K., Lee, Y., & Kim, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242116013 · Cited by 13 · see citing works

Metallothionein Family Proteins as Regulators of Zinc Ions Synergistically Enhance the Anticancer Effect of Cannabidiol in Human Colorectal Cancer Cells

Kwon, I.-S., Hwang, Y.-N., Park, J., Na, H.-H., Kwon, T.-H., Park, J.-S., & Kim, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316621 · Cited by 13 · see citing works

Cannabinoid Analgesia in Postoperative Pain Management: From Molecular Mechanisms to Clinical Reality

Carrascosa, A. J., Navarrete, F., Saldaña, R., García‐Gutiérrez, M. S., Moreno, B. M., Navarro, D., Gómez-Guijarro, F. M., Gasparyan, A., Murcia-Sánchez, E., Torregrosa, A. B., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116268 · Cited by 16 · see citing works

Cannabidiol alters psychophysiological, craving and anxiety responses in an alcohol cue reactivity task: A cross‐over randomized controlled trial

Hurzeler, T. P., Logge, W., Watt, J., McGregor, I. S., Suraev, A. S., Haber, P., & Morley, K. C. (2025) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.15514 · Cited by 13 · see citing works

Molecular Basis of Anxiety: A Comprehensive Review of 2014–2024 Clinical and Preclinical Studies

Merkouris, E., Brasinika, A., Patsiavoura, M., Siniosoglou, C., Tsiptsios, D., Triantafyllis, A. S., Mueller, C., Mpikou, I., Samara, M. T., Christodoulou, G. N., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115417 · Cited by 13 · see citing works

Unveiling behavioral and molecular neuroadaptations related to the antidepressant action of cannabidiol in the unpredictable chronic mild stress model

García‐Gutiérrez, M. S., Navarro, D., Austrich-Olivares, A., & Manzanares, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1171646 · Cited by 12 · see citing works

The two synthetic cannabinoid compounds 4′‐ F‐CBD and HU ‐910 efficiently restrain inflammatory responses of brain microglia and astrocytes

Pereira, M. D. S., Santos, B. M., Giménez, R., Guimarães, F. S., Raisman‐Vozari, R., Bel, E. A. D., & Michel, P. P. (2023) · Glia · doi:10.1002/glia.24489 · Cited by 12 · see citing works

Is the Cannabidiol Potentially Useful for the Treatment of Neuropsychiatricand Drug-Use Disorders?

Manzanares, J., & García‐Gutiérrez, M. S. (2017) · Research and reviews in biosciences · Cited by 1 · see citing works

Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment

Premoli, M., Aria, F., Bonini, S. A., Maccarinelli, G., Gianoncelli, A., Pina, S. D., Tambaro, S., Memo, M., & Mastinu, A. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.03.053 · Cited by 125 · see citing works

Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders

Campos, A. C., Moreira, F. A., Gomes, F. V., Del Bel, E. A., & Guimarães, F. S. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2011.0389 · Cited by 475 · see citing works

Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview

Mandolini, G. M., Lazzaretti, M., Pigoni, A., Oldani, L., Delvecchio, G., & Brambilla, P. (2018) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796018000239 · Cited by 89 · see citing works

Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis sativa

Schier, A. R. D. M., Ribeiro, N. D. C. R., Coutinho, D. C. O., Machado, S. E. D. C., Arias-Carrión, Ó., Crippa, J. A. S., Zuardi, A. W., Nardi, A. E., & Silva, A. R. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666140612114838 · Cited by 154 · see citing works